Boundless Bio Inc. has released a corporate presentation detailing its latest developments in cancer treatment targeting oncogene amplified cancers, which represent a significant unmet medical need with approximately 1.3 million new patients annually in major markets. The company highlights its focus on therapies directed at extrachromosomal DNA (ecDNA), a cancer-specific circular DNA implicated in oncogene amplification. Boundless Bio's drug discovery platform, Spyglass, is used to identify synthetic lethal targets in these cancers. The company’s pipeline includes BBI-940, an oral Kinesin degrader with an accepted IND and a clinical trial set to begin in the first half of 2026. In addition, four other ecDNA-selective targets are under development, with one at the hit-to-lead stage. Boundless Bio reports a cash runway expected to last into the second half of 2028, supporting continued research and development activities. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boundless Bio Inc. published the original content used to generate this news brief on January 20, 2026, and is solely responsible for the information contained therein.